Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK and Anacor form viral and bacterial disease partnership

GSK and Anacor form viral and bacterial disease partnership

9th October 2007

GlaxoSmithKline (GSK) and Anacor Pharmaceuticals have formed a global strategic alliance for the discovery, development and marketing of innovative compounds for the treatment of viral and bacterial infections.

Under the terms of the deal, GSK will pay Anacor an initial fee of $12 million (5.9 million pounds) in addition to a $10 million equity financing commitment.

In exchange, GSK has been granted access to the boron-based chemistry of Anacor for use against up to four selected discovery targets, with the ability to develop at least eight product options.

Anacor will bear the main responsibility for the clinical proof-of-concept development small molecule drug candidates containing boron, with GSK having an exclusive license to license these drugs for further global development.

Zhi Hong, senior vice-president and head of the Infectious Diseases Centre of Excellence for Drug Discovery (ID CEED) at GSK, said: “Anacor’s boron-based chemistry has shown promise in inhibiting targets that are difficult to address with traditional carbon-based molecules and we look forward to further exploring its potential to provide new antiviral and antibiotic options.”

He added that the firm is aware of concerns relating to resistance to existing drugs and is exploring new approaches that offer new avenues for drug development for a number of infectious conditions.

In March 2007, GSK announced the formation of the ID CEED, with Zhi Hong appointed to lead the centre.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.